Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Recombinant Leishmania Major Lipophosphoglycan 3 Activates Human T-Lymphocytes Via Tlr2-Independent Pathway Publisher Pubmed



Hosseini M1, 2 ; Fatahaliha MH1, 2 ; Aghebatimaleki L2 ; Pour AM2 ; Rafati S4 ; Seifinajmi M2 ; Younesi V5 ; Jadidiniaragh F5 ; Yousefi M2
Authors

Source: Journal of Immunotoxicology Published:2016


Abstract

Leishmaniasis is one of the most common infectious diseases transmitted by an obligate intracellular genus Leishmania. As there is no efficient vaccination strategy for leishmaniasis, new immunostimulatory components may enhance protective immune responses against this parasite. Lipophosphoglycan 3 (LPG3) is an essential protein required for LPG assembling. In this study, the ability of recombinant LPG3 (rLPG) and its fragments to activate isolated healthy human T-cells and cytokine secretion was evaluated in vitro. The results showed that rLPG3 and its N-terminal fragment (rNT-LPG3) enhanced expression of CD69 on the surface of T-cells and promoted differentiation of CD4+ T-lymphocytes toward a T-helper 1 (TH1) phenotype, in part, through up-regulation of interferon (IFN)-γ expression in a TLR2-independent manner. These results indicated the protective effects of LPG3 (particularly NT-LPG3 fragment) as a potent immunostimulatory component of leishmania in vaccination against leishmaniasis. Further investigations in in vivo assays are clearly warranted. © 2015 Informa UK Limited trading as Taylor & Francis Group.
Other Related Docs
8. Unraveling the Role of Natural Killer Cells in Leishmaniasis, International Immunopharmacology (2023)
14. Proteomic-Based Studies on Leishmania, Journal of Mazandaran University of Medical Sciences (2018)
17. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)
19. Potential Biomarkers of Immune Protection in Human Leishmaniasis, Medical Microbiology and Immunology (2021)